共 71 条
[1]
Chaparro M(2011)Long-term durability of infliximab treatment in Crohn’s disease and efficacy of dose “escalation” in patients losing response J Clin Gastroenterol 45 113-118
[2]
Panes J(2012)Long-term durability of response to adalimumab in Crohn’s disease Inflamm Bowel Dis 18 685-690
[3]
Garcia V(2009)Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review Am J Gastroenterol 104 760-767
[4]
Chaparro M(2012)Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease Aliment Pharmacol Ther 35 971-986
[5]
Panes J(2015)Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease Gastroenterology 148 e1323-834
[6]
Garcia V(2016)OP029 Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohn’s disease: a prospective, randomised, multicentre trial (Tailorix) J Crohns Colitis 10 S24-25
[7]
Gisbert JP(2017)American Gastroenterological Association Institute Clinical Guidelines C. American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease Gastroenterology 153 827-538
[8]
Panes J(2017)3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management J Crohns Colitis 11 3-771
[9]
Chaparro M(2013)Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn’s disease Ther Drug Monit 35 530-1338
[10]
Guerra I(2012)Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays Aliment Pharmacol Ther 36 765-381